EMQs in Clinical Medicine.pdf - Peshawar Medical College
EMQs in Clinical Medicine.pdf - Peshawar Medical College
EMQs in Clinical Medicine.pdf - Peshawar Medical College
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
20 Cardiovascular medic<strong>in</strong>e<br />
D<br />
I<br />
F<br />
A<br />
A patient with AF of longer than 48 h duration is at risk of<br />
thromboembolism after cardioversion. Unless the patient is severely<br />
compromised, it is standard practice to anticoagulate the patient with<br />
warfar<strong>in</strong> for a month before attempt<strong>in</strong>g elective cardioversion. Dur<strong>in</strong>g<br />
that time the ventricular rate is controlled by prescrib<strong>in</strong>g digox<strong>in</strong>.<br />
Initial therapy <strong>in</strong> a 60-year-old woman present<strong>in</strong>g severely<br />
compromised with acute persistent AF.<br />
In this case immediate DC shock is <strong>in</strong>dicated because the patient is<br />
severely compromised. The adm<strong>in</strong>istration of hepar<strong>in</strong> decreases but does<br />
not abolish the risk of thromboembolism after cardioversion.<br />
A 55-year-old man admitted with an acute myocardial <strong>in</strong>farction<br />
develops a short run of VT. He requires treatment for prophylaxis<br />
aga<strong>in</strong>st recurrent VT.<br />
Amiodarone has class I, II, III and IV actions but is used cl<strong>in</strong>ically for its<br />
class III actions. Class III drugs prolong the plateau phase of the cardiac<br />
action potential and <strong>in</strong>crease the absolute refractory period. As a<br />
consequence they also prolong the Q–T <strong>in</strong>terval.<br />
Amiodarone is the drug of choice to treat VT. When it is used chronically<br />
it has a number of adverse effects but these are not an issue <strong>in</strong> the acute<br />
scenario. These adverse effects <strong>in</strong>clude bradycardia, pulmonary fibrosis,<br />
hepatic fibrosis, corneal microdeposits (regress if drug is stopped),<br />
photosensitive rash and thyroid dysfunction.<br />
Drug to aid diagnosis <strong>in</strong> a 50-year-old man present<strong>in</strong>g with an<br />
unidentifiable, regular, narrow-complex tachycardia.<br />
Adenos<strong>in</strong>e causes profound short-term AV block. In this way it can be<br />
used to term<strong>in</strong>ate tachycardias <strong>in</strong>volv<strong>in</strong>g an AV re-entry circuit. It may<br />
also be used <strong>in</strong> the diagnosis of an unidentified arrhythmia. Adenos<strong>in</strong>e<br />
can cause bronchoconstriction and stimulates nociceptive afferent<br />
neurons <strong>in</strong> the heart. The patient should be warned <strong>in</strong> advance that<br />
he may experience symptoms of chest pa<strong>in</strong> after the drug is<br />
adm<strong>in</strong>istered.<br />
E<br />
Prophylaxis of ventricular tachycardia <strong>in</strong> a patient with vary<strong>in</strong>g QRS<br />
axis and prolonged Q–T <strong>in</strong>terval.<br />
This is torsades de po<strong>in</strong>ts, which will often degenerate to ventricular<br />
fibrillation lead<strong>in</strong>g to cardiac arrest. Causes <strong>in</strong>clude drugs, electrolyte<br />
disturbance and congenital long Q–T syndrome. Conventional<br />
anti-arrhythmics will make this condition worse.<br />
The treatment of choice is <strong>in</strong>travenous magnesium sulphate and<br />
ventricular pac<strong>in</strong>g at a high rate.